Durvalumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Solid Tumor
Conditions
Solid Tumor
Trial Timeline
Sep 5, 2019 → Oct 31, 2024
NCT ID
NCT04078152About Durvalumab
Durvalumab is a approved stage product being developed by AstraZeneca for Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT04078152. Target conditions include Solid Tumor.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06992609 | Phase 3 | Recruiting |
| NCT06826677 | Pre-clinical | Completed |
| NCT05925530 | Phase 2 | Active |
| NCT04944173 | Phase 2 | Withdrawn |
| NCT05924880 | Phase 3 | Completed |
| NCT05617963 | Phase 2 | Recruiting |
| NCT05683977 | Pre-clinical | Active |
| NCT05303532 | Phase 3 | Recruiting |
| NCT05215106 | Phase 2 | Recruiting |
| NCT04416633 | Approved | Completed |
| NCT05933044 | Pre-clinical | Completed |
| NCT04765709 | Phase 2 | Terminated |
| NCT04667312 | Pre-clinical | Completed |
| NCT04062708 | Phase 2 | Active |
| NCT04230408 | Phase 2 | Completed |
| NCT04441138 | Phase 2 | Terminated |
| NCT05267392 | Phase 1/2 | UNKNOWN |
| NCT04543110 | Phase 2 | UNKNOWN |
| NCT04716946 | Phase 2 | Active |
| NCT04642469 | Phase 3 | Completed |
Competing Products
20 competing products in Solid Tumor